China
· Delayed Price · Currency is CNY Shanghai RAAS Blood Products Statistics
Total Valuation
Shanghai RAAS Blood Products has a market cap or net worth of CNY 47.69 billion. The enterprise value is 43.99 billion.
| Market Cap | 47.69B |
| Enterprise Value | 43.99B |
Important Dates
The next estimated earnings date is Friday, April 18, 2025.
| Earnings Date | Apr 18, 2025 |
| Ex-Dividend Date | Sep 30, 2024 |
Share Statistics
Shanghai RAAS Blood Products has 6.60 billion shares outstanding. The number of shares has decreased by -1.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 6.60B |
| Shares Change (YoY) | -1.45% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 29.99% |
| Float | 4.39B |
Valuation Ratios
The trailing PE ratio is 26.15 and the forward PE ratio is 18.28. Shanghai RAAS Blood Products's PEG ratio is 1.66.
| PE Ratio | 26.15 |
| Forward PE | 18.28 |
| PS Ratio | 5.74 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.66 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.35, with an EV/FCF ratio of 98.81.
| EV / Earnings | 24.04 |
| EV / Sales | 5.27 |
| EV / EBITDA | 18.35 |
| EV / EBIT | 19.50 |
| EV / FCF | 98.81 |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.21 |
| Quick Ratio | 2.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 23,352.86 |
Financial Efficiency
Return on equity (ROE) is 6.00% and return on invested capital (ROIC) is 4.62%.
| Return on Equity (ROE) | 6.00% |
| Return on Assets (ROA) | 4.32% |
| Return on Capital (ROIC) | 4.62% |
| Revenue Per Employee | 2.56M |
| Profits Per Employee | 562,286 |
| Employee Count | 3,254 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.75% in the last 52 weeks. The beta is 0.49, so Shanghai RAAS Blood Products's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -9.75% |
| 50-Day Moving Average | 7.46 |
| 200-Day Moving Average | 7.36 |
| Relative Strength Index (RSI) | 37.86 |
| Average Volume (20 Days) | 37,417,944 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shanghai RAAS Blood Products had revenue of CNY 8.34 billion and earned 1.83 billion in profits. Earnings per share was 0.28.
| Revenue | 8.34B |
| Gross Profit | 3.31B |
| Operating Income | 2.26B |
| Pretax Income | 2.26B |
| Net Income | 1.83B |
| EBITDA | 2.39B |
| EBIT | 2.26B |
| Earnings Per Share (EPS) | 0.28 |
Balance Sheet
The company has 3.71 billion in cash and 1.56 million in debt, giving a net cash position of 3.71 billion or 0.56 per share.
| Cash & Cash Equivalents | 3.71B |
| Total Debt | 1.56M |
| Net Cash | 3.71B |
| Net Cash Per Share | 0.56 |
| Equity (Book Value) | 31.17B |
| Book Value Per Share | 4.70 |
| Working Capital | 6.93B |
Cash Flow
In the last 12 months, operating cash flow was 853.06 million and capital expenditures -407.85 million, giving a free cash flow of 445.21 million.
| Operating Cash Flow | 853.06M |
| Capital Expenditures | -407.85M |
| Free Cash Flow | 445.21M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 39.64%, with operating and profit margins of 27.04% and 21.93%.
| Gross Margin | 39.64% |
| Operating Margin | 27.04% |
| Pretax Margin | 27.09% |
| Profit Margin | 21.93% |
| EBITDA Margin | 28.70% |
| EBIT Margin | 27.04% |
| FCF Margin | 5.34% |
Dividends & Yields
This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 0.51%.
| Dividend Per Share | 0.04 |
| Dividend Yield | 0.51% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 23.16% |
| Buyback Yield | 1.45% |
| Shareholder Yield | 1.97% |
| Earnings Yield | 3.82% |
| FCF Yield | 0.93% |
Stock Splits
The last stock split was on September 28, 2016. It was a forward split with a ratio of 1.8.
| Last Split Date | Sep 28, 2016 |
| Split Type | Forward |
| Split Ratio | 1.8 |
Scores
Shanghai RAAS Blood Products has an Altman Z-Score of 14.47.
| Altman Z-Score | 14.47 |
| Piotroski F-Score | n/a |